BioSpace News Archive

Gracell Biotechnologies Inc. announced the details of its poster presentation at the American Association for Cancer Research Annual Meeting 2022, being held from April 8-13 in New Orleans, Louisiana.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), today announced that it is scheduled to present new preclinical data on PH-894, Phio’s self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4), in an in-person poster session at the AACR Annual Meeting 2022.

OnQuality Pharmaceuticals (“OnQuality”), today announced it will be giving an oral presentation highlighting preclinical data for its therapeutic candidate OQL051, a gut-restricted CDK4/6 inhibitor for the prevention of chemotherapy-induced diarrhea (CID), at the American Association for Cancer Research (AACR) Annual Meeting 2022.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from two oncology drug candidates in its pipeline will be presented at the upcoming American Association for Cancer Research Annual Meeting 2022 to be held April 8 – 13, 2022.

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced plans to present new data for multiple research programs across its portfolio of cis-targeted immunotherapies at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Xencor, Inc. (NASDAQ: XNCR), today announced it will present preclinical data on two novel XmAb® cytokine programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 8-13, 2022 at the New Orleans Ernest N. Morial Convention Center in New Orleans.

GlycoMimetics, Inc. announced that the Company will participate at the 34th Annual Roth Conference in Laguna Niguel, California, March 14 and 15.

Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that an abstract has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, scheduled for April 8-13 in New Orleans.

Elephas Biosciences Corporation announced the acceptance of three abstracts by the American Association for Cancer Research.

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the data from its oncology programs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022.